# Observational Carcinoma, Hepatocellular studies: 215 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 215 trials that are observational for Carcinoma, Hepatocellular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational Carcinoma, Hepatocellular studies: 215 rows for $10.75, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 215
- Recruiting or not yet: 215
- Read on: November 19, 2026

## Trials

The 25 newest of 215, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946445 | Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde... | Institute of Liver and Biliary Sciences, India | Observational | Not yet recruiting | Choledocholithiasis, Biliary Stricture, Chronic Pancreatitis, Periampullary Carcinoma, Cholangiocar.... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946445) |
| November 17, 2026 | NCT07942025 | 90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma | Beijing Tsinghua Chang Gung Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942025) |
| October 29, 2026 | NCT07904494 | Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular... | Assiut University | Observational | Not yet recruiting | Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular... | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904494) |
| October 19, 2026 | NCT07880106 | Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Recruiting | Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Breast Cancer | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880106) |
| October 7, 2026 | NCT07863258 | STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma | Universitaire Ziekenhuizen KU Leuven | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863258) |
| September 30, 2026 | NCT07850882 | A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for... | Sponsor not shown (see the record) | Observational | Recruiting | Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850882) |
| September 30, 2026 | NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | Beijing Municipal Administration of Hospitals | Observational | Recruiting | Hepatocellular Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848750) |
| September 24, 2026 | NCT07840092 | Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma | Tianjin Medical University Cancer Institute and Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840092) |
| September 24, 2026 | NCT07839767 | Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence | The University of Hong Kong | Observational | Recruiting | HCC - Hepatocellular Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839767) |
| September 24, 2026 | NCT07838415 | Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical... | Tongji Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC), Treatment Response | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838415) |
| September 23, 2026 | NCT07836309 | TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) | Zhongda Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 596 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836309) |
| September 11, 2026 | NCT07815054 | Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With... | The First Hospital of Jilin University | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815054) |
| September 10, 2026 | NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study | Mansoura University | Observational | Recruiting | HCC - Hepatocellular Carcinoma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814014) |
| September 10, 2026 | NCT07811687 | Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function | Northern Jiangsu People's Hospital | Observational | Recruiting | Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811687) |
| September 8, 2026 | NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | Tam Anh Research Institute | Observational | Recruiting | HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial... | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808164) |
| September 8, 2026 | NCT07807475 | DNP-MRSI of HCC Metabolism to Predict Therapeutic Response | Abramson Cancer Center at Penn Medicine | Observational | Recruiting | Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC) | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807475) |
| August 26, 2026 | NCT07786792 | Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786792) |
| August 24, 2026 | NCT07782632 | Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | Anhui Provincial Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 467 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782632) |
| August 21, 2026 | NCT07780357 | HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B | Beijing Friendship Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780357) |
| August 14, 2026 | NCT07764835 | Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) | D'Or Institute for Research and Education | Observational | Not yet recruiting | Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764835) |
| August 5, 2026 | NCT07748481 | Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for... | The First Hospital of Jilin University | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748481) |
| July 29, 2026 | NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | Shanghai Zhongshan Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734857) |
| July 29, 2026 | NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | University of Oklahoma | Observational | Not yet recruiting | Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732686) |
| July 27, 2026 | NCT07727759 | CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure | Minia University | Observational | Recruiting | Post-Hepatectomy Liver Failure, Liver Failure, Liver Neoplasms, Carcinoma, Hepatocellular, Liver Metastases... | 1,070 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727759) |
| July 24, 2026 | NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable... | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724951) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 9 |
| Shanghai Zhongshan Hospital | 7 |
| Assistance Publique - Hôpitaux de Paris | 6 |
| Tongji Hospital | 5 |
| Assiut University | 5 |
| Beijing Tsinghua Chang Gung Hospital | 5 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| Sun Yat-sen University | 4 |
| The First Hospital of Jilin University | 4 |
| Zhejiang University | 4 |
| University of Oxford | 4 |
| Zhujiang Hospital | 3 |
| Second Affiliated Hospital of Xi'an Jiaotong University | 3 |
| Seoul National University Hospital | 3 |
| Fujian Provincial Hospital | 3 |
| Nanfang Hospital, Southern Medical University | 3 |
| West China Hospital | 3 |
| Sohag University | 3 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 3 |
| City of Hope Medical Center | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| Zhongda Hospital | 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Peking Union Medical College Hospital | 2 |
| University of Belgrade | 2 |

## By country

| Country | Trials |
| --- | --- |
| China | 70 |
| United States | 25 |
| Italy | 24 |
| United Kingdom | 11 |
| France | 9 |
| Egypt | 7 |
| South Korea | 7 |
| Belgium | 7 |
| Germany | 5 |
| Netherlands | 5 |
| Sweden | 5 |
| Japan | 4 |
| Austria | 4 |
| Hong Kong | 4 |
| Spain | 3 |
| Australia | 3 |
| Canada | 3 |
| Turkey (Türkiye) | 2 |
| Serbia | 2 |
| Argentina | 2 |
| Switzerland | 2 |
| Taiwan | 2 |
| Kuwait | 1 |
| Morocco | 1 |
| Qatar | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Employment law firms in the United States](https://specstream.ai/data/businesses/employment-law-firms/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Oncology practices in the United States](https://specstream.ai/data/businesses/oncology-practices/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
